Brickell Biotech Inc

-0.01 (-1.68%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)34.92M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.15 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$0.33
50-Day MA$0.51
200-Day MA$0.81
See more pivots

Brickell Biotech Inc Stock, NASDAQ:BBI

5777 Central Avenue, Suite 102, Boulder, Colorado 80301
United States of America
Phone: +1.720.505.4755
Number of Employees: 13


Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.